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, largely because dysregulation of ErbB proteins is a key factor in progression of many human cancers [3] [4] [5] .
The epidermal growth factor (EGF), which binds to EGFR/ErbB1, was one of the first growth factors to be described [6] . [7] . In contrast, the dimerization arm of ErbB2 is constitutively exposed in the absence of ligand, and no known soluble ligand binds to ErbB2. Nevertheless, ErbB2 is the preferred dimerization partner due to its conformation (for a review, see [4] [9, 10] . This again activates gene transcription resulting in new proteins responsible for proliferation, migration, adhesion, differentiation and apoptosis [1, 8] . Also proteins involved in endocytic down-regulation can be recruited to phosphorylated ErbB proteins, but only activated EGFR seems to be efficiently endocytosed and sorted to lysosomes for degradation [1, 11] (see Fig. 1B [16] . Such EGFR mutations are often found in the first four exons of the kinase domain [16] , directly dysregulating the kinase activity. Another example of EGFR mutant with constitutive signalling is EGFRvIII, which is characterized by a large extracellular deletion [3] . EGFRvIII is expressed in several cancer types, especially in glioblastomas and is sufficient to cause cell transformation [3, 17] . [19, 20] [21] [22] [23] [24] . Furthermore, it was reported that activation of EGFR induces the formation of clathrin-coated pits, by a mechanism requiring EGFR kinase activity [13] . It was recently proposed that EGFR dimerization is sufficient to induce endocytosis of kinase-dead EGFR [25] . [26] [28] . Such internalization could enhance the cytotoxic effect of combining chemotherapy and EGFR-targeting drugs [28] . By temporarily preventing EGFR-mediated survival signalling, the cytotoxic effects of drugs like cisplatin could be enhanced. [12, [29] [30] [31] [32] , it has also been suggested that ubiquitinated EGFR can be endocytosed by a clathrin-independent process. Sigismund and colleagues have proposed that EGFR is endocytosed from caveolae upon exposure to high concentrations of EGF [33] , based on the observation that EGFR is frequently found in such plasma membrane microdomains under these conditions [34, 35] . However, despite the fact that EGFR function seems to be sensitive to the level of caveolin and/or membrane cholesterol [35, 36] , no mobilization of caveolae could be found by FRAP analysis when high concentrations of EGF were added [29] . This strongly argues that even though EGFR can localize to caveolae, activated EGFR is not internalized from these invaginations, but from clathrin-coated pits. It has also been demonstrated that EGFR can activate small GTPases, like Cdc42 and Rac, and thereby be endocytosed into macropinosomes [37] . Furthermore, EGFR has been found to be effectively internalized via circular dorsal ruffles or 'waves' [38] . However, induction of macropinocytosis and waves may be restricted to certain cell types or conditions, and there is now good agreement that functional clathrin-coated pits are the general portal for efficient EGFR endocytosis [29] .
EGFR and the three other members of the EGFR family (ErbB2-4) are structurally similar type I transmembrane proteins, yet with noticeable differences in the ligand-binding domain for ErbB2 and the kinase domain for ErbB3. The ligand-binding extracellular domain in ErbB1, 3 and 4 undergoes a major conformational change during ligand binding, exposing a dimerization arm

Although it was proposed that EGFRvIII undergoes a normal endocytic downregulation [18], other groups reported insignificant degradation of EGFRvIII, due to impaired internalization combined with effective recycling of the small pool of internalized EGFR
. It is important to recognize that heterodimers can be responsible for both increased and altered signalling, as well as decreased downregulation of EGFR. A number of excellent reviews have summarized the role of EGFR in signal transduction and carcinogenesis. This review will mostly focus on how EGFR signalling can be terminated or altered by endocytic down-regulation and how EGFR down-regulation can be inhibited in cancer cells.
Endocytosis of EGFR
The requirements for efficient internalization of EGFR, which is a prerequisite for efficient down-regulation, are disputed. Recently, conflicting data on the necessity of EGFR kinase activity, clathrincoated pits and ubiquitination have been published.
Kinase activity
EGFR normally occurs as monomer at the plasma membrane, prior to activation. Ligand binding triggers its dimerization, resulting in kinase activation, tyrosine phosphorylation and endocytosis. It has been published that EGFR kinase activity is required for recruitment of EGFR into clathrin-coated pits and subsequent endocytic down-regulation of EGF-bound EGFR
However, EGFR kinase activity is required for tyrosine phosphorylation in the EGFR tail, and since binding of Grb2 to such phosphorylated tyrosines is key to clathrin-mediated, ligand-dependent endocytosis
Clathrin-coated pits
Whereas it is well established that EGFR is internalized in a clathrin-dependent manner
Ubiquitination
One of the EGFR tyrosine phosphorylation sites (pY1045) provides a direct docking site for the protooncoprotein and ubiquitin ligase, Cbl, which, upon EGFR activation, acts in concert with an E2 ubiquitin-loaded enzyme to covalently bind ubiquitin to lysine residues in the EGFR kinase domain as well as in the C-terminal tail [39] [40] [41] . In addition, Cbl can bind indirectly to the EGFR via Grb2 [40] . Whether the EGFR is mono-or poly-ubiquitinated has been disputed [42] . However, mass spectrometry analysis has clearly demonstrated both forms to occur and revealed that the ubiquitin chains on EGFR are mainly connected through lysine 63 [41] . [41, 44, 45] . However, an EGFR mutant with impaired kinase activity was reported to depend on ubiquitination for internalization [45] . Thus [46] [47] [48] . Epsin proteins have two or three tandem UIMs [48] as well as clathrin-and AP2-interaction motives [49] [50] [51] [52] [53] [54] . Interestingly, while Eps15 localizes to the edge of clathrin-coated pits [46, 47] , epsin was reported to localize along the entire curvature of these pits [47] . [55] . Interestingly, amplification and overexpression of ErbB2 in breast cancer correlates with poor clinical outcome [56] . ErbB2 is normally trapped at the cell surface due to interaction with the molecular chaperone, heat-shock protein 90 (hsp90) and therefore escapes endocytosis [57, 58] . However, geldanamycin and related drugs of lesser toxicity, which specifically bind and inactivate the molecular chaperone Hsp90 [59, 60] , disrupt the stabilizing interaction of Hsp90 with ErbB2 [61] , resulting in degradation of ErbB2 as well as other Hsp90 target proteins (reviewed in [62, 63] ). Remarkably, in addition to being itself endocytosis-deficient, ErbB2 also prevents internalization of EGFR upon heterodimerization [57, 58, 64] [58] . While EGF-induced formation of clathrincoated pits was observed in cells when AP2 had been knocked down by siRNA and in serum-starved cells [13] , EGF-induced formation was under similar conditions strongly inhibited when the cells overexpressed ErbB2 [58] . [70] ). ubiquitin-interacting domain, and it is currently unclear how it recruits ubiquitinated transmembrane proteins [70] .
While it is established (see below) that ubiquitination plays a central role in subcellular sorting and lysosomal degradation of the EGFR, it is still unclear whether ubiquitination is a signal required for initial steps of clathrin-dependent endocytosis. Mutations of EGFR impairing ubiquitination and thereby causing its stabilization have been described in cancer patients. Such EGFR mutants have further been demonstrated to promote growth and to protect against apoptosis [43]. When expressed in transfected cells, EGFR mutants that are inefficiently ubiquitinated are still efficiently endocytosed, arguing that ubiquitination is not required for EGFR internalization
. Epsin UIMs have been reported to efficiently interact with chains of four or more ubiquitins, preferentially those where lysine 63 in ubiquitin is isopeptide-linked to glycine (K63-linked polyubiquitin chains)
This could suggest that ubiquitinated EGFR is captured by Eps15 and subsequently handed off to epsin deeper in the coated pits, in order to be efficiently sequestered within clathrin-coated vesicles pinching off the plasma membrane (Fig. 2). However, the mechanisms involved in recruiting EGFR to clathrin-coated pits remain an open question.
Effects of EGFR-ErbB2 heterodimerization on EGFR internalization
Whereas activated EGFR can in principle form heterodimers with all other ErbB proteins, ErbB2 is its preferred dimerization partner. Upon ErbB2 overexpression, activated EGFR is increasingly incorporated into EGFR-ErbB2 heterodimers
. This effect is ErbB2-concentration-dependent, and inhibition of EGFR endocytosis can be ascribed to blunted EGF-induced formation of clathrin-coated pits and recruitment of EGFR into such microdomains
Mechanisms responsible for impaired EGF-induced coated pit formation in serum-starved cells are still unclear. While it was demonstrated that neither phosphorylation of tyrosines recruiting Grb2 and Cbl, nor
Fig. 2 Tentative model of molecular interactions promoting regulated entry of EGFR into clathrin-coated pits (CCP). Initial recruitment of ubiquitinated EGFR to Eps15 at the rim of CCPs allows for its transfer
Molecular requirements for EGFR sorting in multivesicular endosomes
Whether proteins should be mono-or poly-ubiquitinated for efficient endosomal sorting to occur is presently unclear. While it has been generally accepted that mono-ubiquitination is sufficient for proteins to interact with UIM-containing proteins on the limiting membrane of endosomes [70] [74] . Moreover, Hrs was found to preferentially interact with K63-ubiquitin chains and negligibly with mono-ubiquitin [74] . This is interesting in view of the recently published proteomics studies demonstrating that EGFR occurs in both mono-and poly-ubiquitinated forms and that the polyubiquitin chains are mostly K63-linked [41] .
EGFR mutants, frequently found in human cancer, can escape efficient ubiquitination and thereby avoid lysosomal degradation [75] . Like natural ErbB2, these EGFR mutants have recently been reported to bind Hsp90. The Hsp90 inhibitor geldanamycin, known to induce down-regulation of ErbB2 (see above) has importantly been demonstrated to also promote down-regulation of poorly ubiquitinated EGFR mutants [43, 75] . This potentially opens new treatment avenues for the numerous cancers bearing such EGFR mutations.
